Company: MDCXW
Filing Date: 2025-03-28
Form Type: 253G2
Source: 0001062993-25-006502
Chunk: 157

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-28
Form: 253G2
Chunk 157
---
 discretion, waive the prohibitions contained in this Policy in exceptional circumstances, provided that the person seeking the waiver does not have any undisclosed material information and that making such an exception would not violate any applicable securities laws.

<div align='center'>-5-</div>

3.QUESTIONS & ENFORCEMENT

3.1This Policy presents only a general framework of the restrictions imposed by securities legislation. The directors, officers and other employees of the Company bear the ultimate responsibility for complying with securities legislation and should therefore view this Policy as the minimum criteria for compliance with such securities legislation and should obtain additional guidance when uncertainty exists regarding a contemplated transaction.

3.2Failure to comply with this Policy or the procedures set out herein may result in disciplinary action, which may include termination of employment. Applicable securities legislation provides that a breach of the prohibition against trading in securities with knowledge of undisclosed material information or providing undisclosed material information to others, in addition to civil liability for damages, may result in imprisonment for up to twenty years and/or a fine of up to the greater of (i) $5 million, and (ii) an amount equal to three times the profit obtained or loss avoided by reason of the contravention. Penalties may also be levied by applicable securities regulatory authorities for not complying with the requirement to file insider reports.

3.3Any questions concerning this Policy should be directed to the Chief Executive Officer or the Chief Financial Officer the Company.

3.4Violations or suspected violations of this Policy should be reported in accordance with the procedures under the Code of Conduct and Ethics of the Company, if any, as amended or replaced from time to time.

Exhibit 23.1

<div align='center'>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

We consent to the incorporation by reference in the Offering Statement of Medicus Pharma Ltd. on Form 1-A (No. 024-12573) of our report dated March 28, 2025, on our audit of the financial statements as of December 31, 2024 and for the year then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 28, 2025. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern.

/s/ EisnerAmper LLP

EISNERAMPER LLP

Philadelphia, Pennsylvania

March 28, 2025

Exhibit 23.2

<div align